Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most mechanism-of-action and disease-state claims are supported only indirectly by the provided label excerpts (which discuss 'Asacol' rather than explicitly 'Asacol HD'). Several claims are non-verifiable/unsupported due to missing wording (e.g., 'extended-release', 'control symptoms', 'absorbed early'). High-priority label sections (contraindications, boxed warnings, dosing safety, and population warnings) were not provided, limiting complete adherence assessment.
Category Scores
Accurate Statements
Asacol HD is used to treat ulcerative colitis.
INDICATIONS AND USAGE: 'Asacol tablets are indicated for the treatment of mildly to moderately active ulcerative colitis...'
Mesalamine products like Asacol HD are used to reduce inflammation in the colon.
DESCRIPTION: 'releasing mesalamine... for topical anti-inflammatory action in the colon.'; CLINICAL PHARMACOLOGY: '...appears to be topical rather than systemic.'
Mesalamine products like Asacol HD are used during periods when ulcerative colitis is active (flares).
INDICATIONS AND USAGE: '...mildly to moderately active ulcerative colitis...'
Unsupported Statements
Asacol HD is an extended-release version of mesalamine.
Provided label excerpts describe 'delayed-release' tablets with pH-dependent dissolution, but do not state 'extended-release.'
Contradictions
Important Omissions
No evaluation possible for contraindications, boxed warnings, and other safety-critical sections because they were not provided in the supplied label excerpts.
Importance:
High
No dosage/dosing and administration details were provided or evaluated against the label excerpts (and dosing safety/monitoring elements are not included).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several product-formulation/PK characterization claims are not fully supported ('extended-release', 'rather than absorbed early'), and label safety sections (contraindications/boxed warnings) were not available, preventing verification of high-priority safety language.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Multiple claims rely on indirect support from 'Asacol' label excerpts rather than explicit 'Asacol HD' wording, and at least one claim ('extended-release') is not evidenced in the provided text.
Suggested Improvement
Restrict claims to what is explicitly supported by the provided label excerpts (e.g., 'delayed-release' with pH-dependent dissolution and topical colon action) and avoid unsupported wording such as 'extended-release' or 'rather than being absorbed early' unless supported by the label text. Provide additional label sections (contraindications, warnings/precautions, dosing/monitoring, and population-specific information) for full adherence scoring.